- Home
- FLGT vs TERN Comparison
FLGT vs TERN Comparison
Compare FLGT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGT
- TERN
- Stock Information
- Founded
- FLGT 2011
- TERN 2017
- Country
- FLGT United States
- TERN United States
- Employees
- FLGT N/A
- TERN N/A
- Industry
- FLGT Medical Specialities
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- FLGT Health Care
- TERN Health Care
- Exchange
- FLGT Nasdaq
- TERN Nasdaq
- Market Cap
- FLGT 697.3M
- TERN 710.6M
- IPO Year
- FLGT 2016
- TERN 2021
- Fundamental
- Price
- FLGT $30.25
- TERN $28.75
- Analyst Decision
- FLGT Buy
- TERN Buy
- Analyst Count
- FLGT 3
- TERN 11
- Target Price
- FLGT $28.33
- TERN $25.59
- AVG Volume (30 Days)
- FLGT 411.7K
- TERN 5.5M
- Earning Date
- FLGT 11-07-2025
- TERN 11-10-2025
- Dividend Yield
- FLGT N/A
- TERN N/A
- EPS Growth
- FLGT N/A
- TERN N/A
- EPS
- FLGT N/A
- TERN N/A
- Revenue
- FLGT $315,549,000.00
- TERN N/A
- Revenue This Year
- FLGT $15.19
- TERN N/A
- Revenue Next Year
- FLGT $10.58
- TERN N/A
- P/E Ratio
- FLGT N/A
- TERN N/A
- Revenue Growth
- FLGT 13.61
- TERN N/A
- 52 Week Low
- FLGT $14.57
- TERN $1.87
- 52 Week High
- FLGT $31.04
- TERN $29.51
- Technical
- Relative Strength Index (RSI)
- FLGT 71.79
- TERN 81.58
- Support Level
- FLGT $28.65
- TERN $25.31
- Resistance Level
- FLGT $31.04
- TERN $28.49
- Average True Range (ATR)
- FLGT 1.33
- TERN 2.00
- MACD
- FLGT 0.21
- TERN 0.49
- Stochastic Oscillator
- FLGT 87.98
- TERN 94.84
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.